BREYANZI is a prescription medicine used to treat large B cell lymphoma, a type of non-Hodgkin lymphoma, when:

  • your first treatment has not worked or your cancer returned within a year of your first treatment OR...Read more

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Powered for remission

Many people responded to Breyanzi® CAR T cell therapy, even after other treatments did not work or stopped working

Breyanzi has been studied in over 400 people across 3 clinical studies. Select a tab to see the clinical studies that evaluated Breyanzi CAR T cell therapy when used as either a second or later line of treatment.

Study 1: The power for more time without an event

About this study

Who was in this study?

  • 184 people with large B-cell lymphoma
  • Everyone had previously received 1 line of treatment that either did not work or stopped working within 12 months after the first treatment given

What was the goal of the study?

  • To determine the safety and efficacy of Breyanzi compared to standard therapy
Hypothetical patient

What treatment was given?

Hypothetical patient receiving CAR T cell therapy treatment and care partner

What treatment was given?

People were randomly put into the following treatment groups:

  • Breyanzi CAR T cell therapy
  • Standard therapy

During the study, people in standard therapy treatment group were able to receive Breyanzi if:

  • They did not respond to standard therapy after 9 weeks
  • The cancer progressed at any time
  • Another medication was needed
more time
without an event

An event was defined as cancer getting worse, failing to respond to cancer therapy, or needing to start a new lymphoma treatment.


With Breyanzi, people had 10.1 months (median) without an event, vs 2.3 months (median) with standard therapy.

Study 2: The power to respond to treatment without stem cell transplant

About this study

Who was in this study?

  • 61 people with large B-cell lymphoma who were not able to receive a stem cell transplant
  • Everyone had received 1 line of treatment that either did not work stopped working

What was the goal of the study?

  • To determine the safety and efficacy of Breyanzi when stem cell transplant is not an option
of people (49/61) responded to Breyanzi

54% of people (33/61) achieved a complete response

Complete response means no signs of cancer were found in the body. Complete response does not mean the cancer has been cured.

26% of people (16/61) achieved a partial response

Partial response means the amount of cancer had been reduced.

within 1 month with one-time* Breyanzi


In the clinical study, complete response, or remission, was seen within 1 month (median) after infusion. For some people, this ranged from 0.8 months to 6.9 months.

Remission is a decrease in, or disappearance of, signs and symptoms of cancer.

*The treatment process includes blood collection, CAR T cell creation, administration, and side-effect monitoring.

These are results experienced by people in the Breyanzi clinical trial. Your results may be different.

Most common side effects with Breyanzi

Side effects are possible and should be managed by your healthcare team.

Hypothetical patient and care partner monitoring side effects

Across all clinical studies, the most common side effects were:

Hypothetical patient and care partner monitoring side effects
  • Fever (100.4°F/38°C or higher)
  • Cytokine release syndrome
  • Being very tired
  • Pain in the muscles and bones
  • Nausea

These are not all the common side effects with Breyanzi. Please see more common side effects below in the Important Safety Information.

Call your healthcare provider or get emergency help right away if you have any of the side effects listed above.

It is important that you tell your healthcare providers that you have received Breyanzi and to show them your Breyanzi Patient Wallet Card. Your healthcare provider may give you other medicines to treat your side effects.

Serious side effects

Breyanzi may cause serious side effects that are life-threatening and can lead to death, such as cytokine release syndrome and neurologic toxicity. Your healthcare team is trained to manage the side effects of Breyanzi.

Cytokine release syndrome (CRS)

Cytokine release syndrome, or CRS, happens when the immune cells release a large amount of proteins, called cytokines, into the blood. Some symptoms of CRS include fever, chills, fast heart rate, headache, and not enough oxygen in the tissue.

In the clinical studies, 45% of people (68/150) experienced CRS that was mild to severe

  • 1.3% of people experienced severe CRS
  • The median time it took for CRS to occur after infusion was 4 days, and the length of time it lasted was a median of 4 days
  • CRS generally occurred 1 to 63 days after receiving Breyanzi and lasted 1 to 16 days

Neurologic toxicity

Neurologic toxicity is a serious side effect of the nervous system. It can cause brain disease, involuntary shaking, difficulty speaking, headache, dizziness, and can make it hard to think clearly.

In the clinical studies, 27% of people (41/150) experienced neurologic toxicity that was mild to severe

  • 7% of people experienced severe neurologic toxicity
  • The median time it took for the first neurologic event to occur after infusion was 8 days, and the length of time it lasted was a median of 6 days
  • Neurologic toxicity generally occurred 1 to 63 days after receiving Breyanzi and lasted 1 to 119 days

If you have a fever (100.4ºF/38ºC or higher) or show any other signs or symptoms of CRS or neurologic toxicity, immediately call your healthcare provider, or go to the emergency room as instructed by your healthcare team.

Study 3: The power of a lasting remission

About this study

Who was in this study?

  • 192 people with large B-cell lymphoma who have had at least 2 other types of treatment that did not work or stopped working

What was the goal of the study?

  • To determine the safety and efficacy of Breyanzi
of people (141/192) responded to Breyanzi

54% of people (104/192) achieved a complete response

Complete response means no signs of cancer were found in the body. Complete response does not mean the cancer has been cured.

19% of people (37/192) achieved a partial response

Partial response means the amount of cancer had been reduced.

In a clinical study, half of the people who received Breyanzi were alive
at 2 years after treatment


Overall survival was not a key measurement in this study, and the impact of treatment on survival has not been established. These data included outcomes from 257 people who completed the original study and joined a follow-up study.

These are the results experienced by people in the Breyanzi clinical study. Your results may be different.

Most common side effects with Breyanzi

Side effects are possible and should be managed by your healthcare team.

Hypothetical patient and care partner monitoring side effects

Across all clinical studies, the most common side effects were:

Hypothetical patient and care partner monitoring side effects
  • Fever (100.4°F/38°C or higher)
  • Cytokine release syndrome
  • Being very tired
  • Pain in the muscles and bones
  • Nausea

These are not all the common side effects with Breyanzi. Please see more common side effects below in the Important Safety Information.

Call your healthcare provider or get emergency help right away if you have any of the side effects listed above.

It is important that you tell your healthcare providers that you have received Breyanzi and to show them your Breyanzi Patient Wallet Card. Your healthcare provider may give you other medicines to treat your side effects.

Serious side effects

Breyanzi may cause serious side effects that are life-threatening and can lead to death, such as cytokine release syndrome and neurologic toxicity. Your healthcare team is trained to manage the side effects of Breyanzi.

Cytokine release syndrome (CRS)

Cytokine release syndrome, or CRS, happens when the immune cells release a large amount of proteins, called cytokines, into the blood. Some symptoms of CRS include fever, chills, fast heart rate, headache, and not enough oxygen in the tissue.

In the clinical study, 46% of people (122/268) experienced CRS toxicity that was mild to life-threatening or fatal

  • 4% of people experienced severe to fatal CRS. One person had fatal CRS and 2 had ongoing CRS at time of death
  • The median time it took for CRS to occur after infusion was 5 days, and the length of time it lasted was a median of 5 days
  • CRS generally occurred 1 to 15 days after receiving Breyanzi and lasted 1 to 17 days

Neurologic toxicity

Neurologic toxicity is a serious side effect of the nervous system. It may cause a condition that could change how the brain works or its structure, as well as shaking that you cannot control, difficulty speaking, headache, dizziness, and can also make it harder to think clearly. These are not all of the signs and symptoms. Call your healthcare team immediately if you notice any changes.

In the clinical study, 35% of people (96/268) experienced neurologic toxicity that was mild to life-threatening or fatal

  • 12% of people experienced severe neurologic toxicity. Three people had fatal neurologic toxicity and 7 had ongoing neurologic toxicity at time of death
  • The median time it took for the first neurologic event to occur after infusion was 8 days, and the length of time it lasted was a median of 12 days
  • Neurologic toxicity generally occurred 1 to 46 days after receiving Breyanzi and lasted 1 to 87 days

If you have a fever (100.4ºF/38ºC or higher) or show any other signs or symptoms of CRS or neurologic toxicity, immediately call your healthcare provider, or go to the emergency room as instructed by your healthcare team.

Learn more about what it is like to get Breyanzi
from people who have received treatment.

SEE STORIES